Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2
Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed…
Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
ASX Announcements
Corporate Governance
Share Price
Latest News
Race Receives Governance Approval for Extramedullary AML & MDS Human Trial
Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO)…
March 2022 Quarterly Activity Report and Appendix 4C
March-2022-Quarterly-Activity-Report-and-Appendix-4CDownload
Cancer Drug Trial
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research…
Race Receives Human Ethics Approval for Extramedullary AML & MDS Trial
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman…
Zantrene Highly Effective in a Mouse Model of Extramedullary AML
Zantrene-Highly-Effective-in-a-Mouse-Model-of-Extramedullary-AMLDownload
